Pureos Bioventures, a Swiss VC investing in pre-clinical and clinical-stage drug developers, plans to raise a second fund of approximately CHF 250m-300m by the end of next year, managing partner Martin Münchbach told Unquote.
Pureos Bioventures, a Swiss VC investing in pre-clinical and clinical-stage drug developers, plans to raise a second fund of approximately CHF 250m-300m by the end of next year, managing partner Martin Münchbach told Unquote.